Abstract Body

Background

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a high potent and simplified antiretroviral therapy (ART) regimen as shown by clinical trials. However, real-world evidence in individuals experiencing a virologic failure (VF) remains limited. We investigated the virological outcomes in participants who experienced VF after switching to B/F/TAF.

Methods

We conducted a retrospective study using data from the French regional prospective cohort ANRS-CO3-AquiVIH-NA. Participants who switched to B/F/TAF between 2018/01/01 and 2021/12/31 with a follow-up (FU) up to 65 months and with a genotypic resistance test (GRT) available before B/F/TAF initiation were included. VF was defined as either 2 consecutive HIV-1 viral loads (VL)>50 cp/mL or 1 VL>1000 cp/mL. GRTs were performed using Sanger sequencing and interpreted using the v34 ANRS resistance algorithm. We described the virological outcomes at the last FU visit or at treatment discontinuation.

Results

Of 636 participants with available GRT at B/F/TAF initiation, 55/636 (8.6%) experienced VF during the study period. Among those, 22/55 were unsuppressed at baseline; with a median [min; max] VL of 140 cp/ml [55; 599,503]. GRTs were performed in 46/55 (83.6%) participants at the time of VF. Resistance associated mutations (RAMs) were detected for 14 of them (30.4%), including 8 with RAMs already documented in a previous GRTs before B/F/TAF initiation. Among the 6 participants without previous RAMs, M184I/V was the only selected mutation. An emergent integrase mutation (R263K) was detected for one individual after 9 months of B/F/TAF. He had an unsuppressed baseline viremia (273,000 cp/mL) and documented M184V + 2 TAMs (D67N T215I) in historical GRTs. After VF, B/F/TAF was maintained in 47/55 (85.5%) participants of whom 28/47 (59.6%) achieved viral suppression, 19/47 (40.4 %) remained unsuppressed; 1/55 (1.8%) was lost of FU, ART regimen was changed in 5/55 (9.1%), and 2/55 (3.6%) died.

Conclusions

The low prevalence (8.6%) of VF confirmed the real-world effectiveness and robustness of B/F/TAF in this study. Emergence of resistance in case of VF occurred rarely (RAMs selected at VF for 6 participants: mostly M184I/V, only one R263K). Poor or inconsistent adherence may explain most of VF cases, as 59.6% of participants in VF achieved viral suppression post-VF with B/F/TAF. This emphasizes the importance of adherence counselling in improving outcomes.

Table or Figure